OLMA
NASDAQOlema Pharmaceuticals Inc.
Price$11.46+0.13 (+1.10%)
01:30 PM07:45 PM
News · 26 weeks74+225%
2026-01-182026-07-12
Mix3390d
- Insider13(39%)
- Other10(30%)
- SEC Filings9(27%)
- Leadership1(3%)
Latest news
25 items- PROlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, July 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to eight new employees to purchase an aggregate of 215,800 shares of the Company's common stock, effective as of July 1, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance
- INSIDERSEC Form 4 filed by See Explanation of Responses Bvf Partners L P/Il4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Harmon Cyrus4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Butitta Cynthia M4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Garland J. Scott4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Hrustanovic Gorjan4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Clark Ian T4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Larson Yi4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Horning Sandra4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Raman Prakash4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Rappaport Andrew4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- INSIDERSEC Form 4 filed by Director Graham G. Walmsley4 - Olema Pharmaceuticals, Inc. (0001750284) (Issuer)
- SECOlema Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
- PROlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, June 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 176,150 shares of the Company's common stock, effective as of June 1, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance wi
- PRLilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to ExplodeDENVER, June 01, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Eli Lilly (NYSE:LLY) has once again captured the attention of the oncology community after reporting remarkably strong Phase 3 results for Retevmo (selpercatinib) in early-stage RET fusion-positive non-small cell lung cancer. The LIBRETTO-432 study demonstrated an 83% reduction in the risk of disease recurrence or death versus placebo, potentially establishing Retevmo as a new standard of care in the adjuvant setting. The data were selected for presentation during the prestigious Plenary Session at the 2026 ASCO Annual Meeting and will be simultaneously published in The New England Journal of Medicine. For investors, the
- SECOlema Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
- PROlema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate CancerStudy to evaluate OP-3136, Olema's novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026First clinical collaboration for OP-3136; results to inform combination strategy in metastatic prostate cancer setting SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced a clinical trial collaboration and supply agreement with Bayer AG ("Bayer") to evaluate OP-3136, Olema's investigational lysine acety
- SECOlema Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
- PROlema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual MeetingOP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse eventsOP-3136 shows evidence of anti-tumor activity across multiple solid tumor typesData support the ongoing Phase 1 evaluation of OP-3136 as a monotherapy and in combination with fulvestrant and palazestrant SAN FRANCISCO, May 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced preliminary clinical data from the Phase 1 study of OP-3
- PROlema Oncology to Participate in Upcoming Investor ConferencesSAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: TD Cowen 7th Annual Oncology Innovation SummitDate and Time: May 26, 2026 at 12:30 p.m. ETFormat: Fireside ChatLocation: Virtual Jefferies Global Healthcare ConferenceDate and Time: June 3, 2026 at 8:45 a.m. ETFormat: Fireside ChatLocation: New York, NY Goldman Sachs 47th Annual Global Healthcare ConferenceDate and Tim
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Olema Pharmaceuticals Inc.SCHEDULE 13G/A - Olema Pharmaceuticals, Inc. (0001750284) (Subject)
- SECSEC Form 10-Q filed by Olema Pharmaceuticals Inc.10-Q - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
- SECOlema Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Olema Pharmaceuticals, Inc. (0001750284) (Filer)
- PROlema Oncology Reports First Quarter 2026 Financial and Operating ResultsTop-line data from the Phase 3 OPERA-01 trial anticipated this fall; Phase 3 OPERA-02 trial continues to enroll patientsFirst clinical data from OP-3136 Phase 1 study to be presented at ASCO Ended the first quarter with $505.3 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, May 12, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the first quarter ended March 31, 2026. "We continued to meaningfully advance ou
- PROlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to five new employees to purchase an aggregate of 154,700 shares of the Company's common stock, effective as of May 1, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance wit
OLMA FAQ
7 questionsWhat does Olema Pharmaceuticals Inc. do?
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema...Where does OLMA stock trade?
Olema Pharmaceuticals Inc. (OLMA) is listed on NASDAQ.What sector and industry is OLMA in?
Olema Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Olema Pharmaceuticals Inc. go public?
Olema Pharmaceuticals Inc. (OLMA) completed its IPO in 2020.What are analysts saying about OLMA?
Olema Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-03-27. Recent price targets range from $2000.00 to $4800.00.What companies are similar to OLMA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare OLMA side-by-side with any of them on Quantisnow.How can I track OLMA on Quantisnow?
Quantisnow aggregates Olema Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OLMA to receive live email and push alerts on every new disclosure.